Credit Suisse’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-164,647
| Closed | -$2.49M | – | 4223 |
|
|
2022
Q3 | $2.49M | Buy |
164,647
+133,596
| +430% | +$1.55M | ﹤0.01% | 1706 |
|
|
2022
Q2 | $233K | Sell |
31,051
-296
| -0.9% | -$2.09K | ﹤0.01% | 3277 |
|
|
2022
Q1 | $284K | Buy |
31,347
+2,056
| +7% | +$15.8K | ﹤0.01% | 3246 |
|
|
2021
Q4 | $205K | Sell |
29,291
-12,922
| -31% | -$135K | ﹤0.01% | 4264 |
|
|
2021
Q3 | $482K | Buy |
42,213
+3,290
| +8% | +$48.1K | ﹤0.01% | 3823 |
|
|
2021
Q2 | $624K | Sell |
38,923
-10,026
| -20% | -$172K | ﹤0.01% | 3699 |
|
|
2021
Q1 | $874K | Buy |
48,949
+6,922
| +16% | +$120K | ﹤0.01% | 3405 |
|
|
2020
Q4 | $568K | Buy |
42,027
+11,711
| +39% | +$142K | ﹤0.01% | 3737 |
|
|
2020
Q3 | $357K | Sell |
30,316
-383,700
| -93% | -$4.67M | ﹤0.01% | 3557 |
|
|
2020
Q2 | $6.11M | Buy |
414,016
+382,740
| +1,224% | +$5.66M | ﹤0.01% | 1581 |
|
|
2020
Q1 | $422K | Buy |
31,276
+361
| +1% | +$6.85K | ﹤0.01% | 3210 |
|
|
2019
Q4 | $747K | Sell |
30,915
-166,126
| -84% | -$3.44M | ﹤0.01% | 3321 |
|
|
2019
Q3 | $3.79M | Buy |
197,041
+48,753
| +33% | +$1.12M | ﹤0.01% | 1979 |
|
|
2019
Q2 | $4.38M | Buy |
148,288
+116,154
| +361% | +$4.48M | ﹤0.01% | 1845 |
|
|
2019
Q1 | $1.53M | Buy |
32,134
+2,326
| +8% | +$102K | ﹤0.01% | 2575 |
|
|
2018
Q4 | $1.08M | Sell |
29,808
-215,538
| -88% | -$10.1M | ﹤0.01% | 2718 |
|
|
2018
Q3 | $15.1M | Buy |
245,346
+8,263
| +3% | +$531K | 0.01% | 1020 |
|
|
2018
Q2 | $16M | Sell |
237,083
-93,177
| -28% | -$5.21M | 0.02% | 957 |
|
|
2018
Q1 | $17.9M | Buy |
330,260
+150,757
| +84% | +$8.43M | 0.02% | 913 |
|
|
2017
Q4 | $10.7M | Buy |
179,503
+62,714
| +54% | +$3.8M | 0.01% | 1241 |
|
|
2017
Q3 | $5.68M | Buy |
116,789
+60,678
| +108% | +$3.31M | 0.01% | 1671 |
|
|
2017
Q2 | $2.95M | Sell |
56,111
-28,190
| -33% | -$1.31M | ﹤0.01% | 1972 |
|
|
2017
Q1 | $3.82M | Buy |
84,301
+19,885
| +31% | +$887K | ﹤0.01% | 1851 |
|
|
2016
Q4 | $2.44M | Buy |
64,416
+39,218
| +156% | +$1.48M | ﹤0.01% | 2284 |
|
|
2016
Q3 | $951K | Sell |
25,198
-11,495
| -31% | -$253K | ﹤0.01% | 3003 |
|
|
2016
Q2 | $646K | Sell |
36,693
-37,918
| -51% | -$614K | ﹤0.01% | 3265 |
|
|
2016
Q1 | $908K | Buy |
74,611
+31,327
| +72% | +$496K | ﹤0.01% | 2802 |
|
|
2015
Q4 | $1.05M | Buy |
43,284
+29,766
| +220% | +$695K | ﹤0.01% | 2770 |
|
|
2015
Q3 | $239K | Sell |
13,518
-29,122
| -68% | -$527K | ﹤0.01% | 3839 |
|
|
2015
Q2 | $753K | Buy |
42,640
+18,688
| +78% | +$343K | ﹤0.01% | 3415 |
|
|
2015
Q1 | $751K | Buy |
23,952
+885
| +4% | +$25.7K | ﹤0.01% | 3218 |
|
|
2014
Q4 | $674K | Buy |
+23,067
| New | +$585K | ﹤0.01% | 3481 |
|
|
2014
Q3 | – | Sell |
-11,175
| Closed | -$277K | – | 4706 |
|
|
2014
Q2 | $277K | Sell |
11,175
-6,259
| -36% | -$108K | ﹤0.01% | 4163 |
|
|
2014
Q1 | $370K | Buy |
+17,434
| New | +$352K | ﹤0.01% | 3941 |
|
Credit Suisse's AERI Position: Q4 2022 in Review
Credit Suisse sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 164,647 shares — an estimated $2.49M sold.
Credit Suisse first reported a position in AERI in Q1 2014 and held it in 34 quarters. The position peaked at $17.9M in Q1 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Credit Suisse reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Credit Suisse sold 164,647 Aerie Pharmaceuticals shares in Q4 2022, an estimated $2.49M.
- Credit Suisse first reported a position in Aerie Pharmaceuticals in Q1 2014 and held it in 34 quarters.
- Credit Suisse's Aerie Pharmaceuticals position peaked at $17.9M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.